CureVac

GSK will receive $370 million upfront from CureVac following a patent settlement involving BioNTech and Pfizer over mRNA vaccine technology, with $320 million paid in cash.

BioNTech will lay off 63 employees and wind down cell therapy manufacturing at its Gaithersburg, Maryland facility by the end of 2025 following disappointing Phase 1 trial results.

BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities.

Ethris and Lonza have formed a strategic partnership to develop spray-dried mRNA vaccines for respiratory diseases that remain stable at room temperature, eliminating cold chain requirements.

CureVac has received FDA clearance for its Investigational New Drug application to begin Phase 1 trials of CVHNLC, an mRNA-based precision immunotherapy targeting squamous non-small cell lung cancer.

European Patent Office largely upholds CureVac's patent EP 3 708 668 B1 for split poly-A tail technology, a foundational mRNA innovation, dismissing BioNTech's opposition challenge.

Personalized cancer vaccines are emerging as a transformative approach in oncology, with BioNTech, Moderna, and myNEO Therapeutics leading development using mRNA technology refined during the COVID-19 pandemic.

Moderna has filed patent infringement lawsuits against Pfizer/BioNTech in multiple countries, claiming their Comirnaty vaccine infringes on mRNA technology patents that Moderna pioneered and invested billions in developing.

METiS Pharmaceuticals has appointed Mark Herbert, former President of Arcturus Therapeutics, as Chief Business Officer to lead global business development and strategic partnerships.

Pfizer and BioNTech have initiated a 25,000-participant Phase 3 trial for their mRNA-based quadrivalent seasonal influenza vaccine, marking the first such advanced trial in the field.